Table 3. Clinicopathological characteristics of FVPTC according to presence of encapsulation.
| Characteristics | Encapsulated FVPTC (n = 3) | Infiltrative FVPTC (n = 19) | P value | |
|---|---|---|---|---|
| Sex | 1.000 | |||
| Male | 1 (33.3) | 5 (26.3) | ||
| Female | 2 (66.6) | 14 (73.7) | ||
| Age, yr | 44.7 ± 16.6 | 55.2 ± 9.7 | 0.388 | |
| Old age (> 45 yr) | 2 (66.6) | 16 (84.2) | 0.470 | |
| Tumor size, cm | 2.7 ± 2.9 | 1.2 ± 0.9 | 0.065 | |
| ETE | 0 (0) | 7 (36.8) | 0.523 | |
| LNM | 0 (0) | 4 (21.1) | 1.000 | |
| Multifocality | 0 (0) | 7 (36.8) | 0.709 | |
| Advanced stage | 1 (33.1) | 8 (42.1) | 1.000 | |
| BRAFV600E mutation | 0 (0) | 6 (31.6) | 0.532 | |
| Halo sign | 3 (100) | 6 (31.6) | 0.055 | |
| ATA high suspicion | 0 (0) | 5 (26.3) | 1.000 | |
Data are expressed as mean ± standard deviation and frequency (%) for categorical variables.
FVPTC = follicular variant papillary thyroid carcinoma, ETE = extrathyroidal extension, LNM = lymph node metastasis, Advanced stage = American Joint Committee on Cancer (AJCC) stage III + IV, ATA = American Thyroid Association.